Valeant Pharmaceuticals Intl (TSE:VRX) (NYSE:VRX) will be releasing its earnings data before the market opens on Wednesday, February 28th. Analysts expect Valeant Pharmaceuticals Intl to post earnings of C$1.23 per share for the quarter.
Valeant Pharmaceuticals Intl (TSE:VRX) opened at C$23.48 on Wednesday. The stock has a market cap of $8,180.00, a price-to-earnings ratio of 4.79 and a beta of -0.89. Valeant Pharmaceuticals Intl has a fifty-two week low of C$11.20 and a fifty-two week high of C$30.56.
A number of research firms have issued reports on VRX. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a C$23.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, November 8th. TD Securities raised shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating and set a C$25.50 price target for the company in a report on Wednesday, November 8th.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.